Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...

The agreement is set to investigate a market-ready proprietary formulation and optimized delivery route for Awakn’s MDMA using Catalent's Zydis orally-disintegrating tablet (ODT) technology, a ...

Psychedelics biotech Awakn Life Sciences AWKNF has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, fast-dissolving tablet Zydis technology ...

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation ...

Forward-looking information in this news release includes, but is not limited to, statements regarding anticipated benefits of incorporating the Zydis ODT delivery technology with MM-120, grant of ...

Calling Zydis “very versatile and effective in developing easy-to-administer dose forms for innovators,” Tom Hawkeswood, president and division head of pharma product delivery at Catalent ...

Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...

Under the terms of the agreement, Melt Pharmaceuticals will utilize Catalent’ s proprietary Zydis ® orally disintegrating tablet fast-dissolve technology with MELT-300, a sublingual, needle ...